M.D. Anderson Cancer Center
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Primary Objective \- To determine the ORR of ivonescimab in patients with cSCC and CRPC Secondary Objectives * To evaluate other indicators of the antitumor efficacy of ivonescimab in patients with cSCC and CRPC. * To evaluate the safety and tolerability of ivonescimab in patients with cSCC and CRPC Exploratory Objective * To evaluate potential predictors of response and resistance to ivonescimab * To bank pre-treatment blood samples for future correlative analyses * To evaluate imaging characteristics predictive of treatment response and side effects
Inclusion Criteria: * Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures. * Age ≥18 years. * Has locally advanced surgically non-appropriate (unresectable and/or metastatic) cSCC (Cohort 1).. * Has metastatic CRPC (Cohort 2): * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology. * Documented prostate cancer progression as documented by PSA progression according to PCWG3 criteria. * Surgically or medically castrated, with serum t…
Given by PO
Arctuva estimate
Verify or correct the compensation shown for this listing.